Equities

Piramal Pharma Ltd

PPLPHARMA:NSI

Piramal Pharma Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (INR)250.15
  • Today's Change4.30 / 1.75%
  • Shares traded3.35m
  • 1 Year change+110.30%
  • Beta--
Data delayed at least 15 minutes, as of Nov 22 2024 10:24 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Piramal Pharma Limited is an India-based pharmaceutical company, which offers a portfolio of differentiated pharma products across a domestic and global distribution network. The Company has approximately 17 global facilities and a global distribution network in over 100 countries. The Company's subsidiaries include Piramal Pharma Solutions (PPS), an integrated contract development and manufacturing organization; Piramal Critical Care (PCC), a complex hospital generics business, and the India consumer healthcare business selling over-the-counter products. PPS offers end-to-end development and manufacturing solutions through a globally integrated network of facilities across the drug life cycle to generic companies. PCC's complex hospital product portfolio includes inhalation anesthetics, intrathecal therapies for spasticity and pain management, injectable pain, anesthetics, injectable anti-infectives, and other therapies.

  • Revenue in INR (TTM)87.04bn
  • Net income in INR453.30m
  • Incorporated2020
  • Employees6.72k
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Neuland Laboratories Ltd.15.28bn2.80bn189.47bn1.65k67.7513.6555.1412.40217.98217.981,191.201,081.520.8472.144.859,273,565.0015.509.2520.0312.7152.1447.8118.3011.991.4031.560.07287.1330.8418.5183.5178.7617.8863.45
Wockhardt Ltd29.49bn-2.88bn190.86bn2.39k--5.31--6.47-19.85-19.85201.29221.320.3931.874.1912,318,300.00-3.93-4.56-6.33-8.2959.1055.26-10.00-12.700.56770.2470.3869--5.55-4.7317.17---4.71--
Alembic Pharmaceuticals Ltd63.57bn6.47bn204.00bn14.86k31.564.1722.063.2132.8832.88323.14248.680.9290.93665.434,278,678.009.4510.7213.3214.2573.8465.9810.1712.470.805712.620.179128.2910.199.6280.071.05-15.5914.87
Concord Biotech Ltd10.86bn3.28bn208.31bn1.38k53.7613.1054.5819.1937.0437.04114.79152.020.6551.113.557,884,886.0019.78--21.82--76.00--30.20--4.83194.730.0022--19.20--28.33------
Pfizer Ltd22.38bn6.18bn234.75bn1.72k37.996.2634.5810.49135.06135.06489.19819.900.52881.8311.1613,004,360.0014.6014.2217.0517.7165.0061.3727.6124.054.3046.210.026782.67-9.551.05-11.645.1433.359.24
Emcure Pharmaceuticals Ltd72.56bn5.67bn242.76bn11.15k42.275.8925.283.3530.3730.37389.63217.790.9781.803.966,510,068.008.027.1413.5513.9361.1159.298.207.810.95495.250.21650.0011.237.14-6.3621.35-5.93--
Natco Pharma Ltd.45.61bn19.45bn246.23bn4.02k12.663.4411.545.40108.58108.58254.65399.190.62910.89283.5711,356,080.0026.8212.3330.8514.2585.4773.0542.6325.164.19108.700.028318.9647.7213.8194.0916.59-4.7114.87
Laurus Labs Ltd50.53bn1.31bn263.73bn6.01k201.066.3848.375.222.432.4393.7076.700.6021.183.068,412,186.001.5510.132.5216.4753.4447.632.5812.830.58181.810.402313.00-16.5517.07-79.6811.3621.6821.67
J B Chemicals and Pharmaceuticals Ltd37.11bn6.11bn264.35bn5.31k44.278.2334.407.1238.4538.45233.33206.820.94812.594.856,987,882.0015.6115.7718.6218.8966.2661.1816.4716.062.2027.530.030333.0810.6316.2234.8423.3640.1537.42
Gland Pharma Ltd58.90bn6.92bn294.41bn4.22k42.573.3527.385.0041.9841.98357.57533.410.55671.284.1113,967,630.006.5413.237.6514.5660.3055.5811.7422.923.1433.110.03587.2656.2922.61-1.1011.3224.02--
Suven Pharmaceuticals Ltd9.61bn2.43bn324.43bn1.05k133.6416.40106.9333.759.549.5437.7377.710.41561.525.999,136,501.0010.5023.1711.5026.2061.4258.8525.2733.214.0029.500.019118.63-21.5622.71-26.9922.41-1.83--
Piramal Pharma Ltd87.04bn453.30m324.55bn6.72k721.714.1040.343.730.34070.340766.3659.910.57991.404.8812,954,040.000.302--0.428--63.69--0.5208--0.56037.490.3771--15.39--109.56------
Ajanta Pharma Ltd44.91bn8.75bn367.93bn7.84k42.3510.0136.368.1969.5569.55356.94294.360.97381.334.165,725,128.0018.9716.6123.2920.4775.7773.2219.4819.312.1349.880.008831.2012.4515.4138.8116.10-14.9710.76
IPCA Laboratories Ltd85.33bn6.61bn399.22bn17.34k60.375.9637.424.6826.0726.07336.37264.100.74831.124.784,922,642.005.8810.339.0013.5267.3659.167.8512.251.3225.330.12912.8623.3915.3516.134.2417.9021.67
GlaxoSmithKline Pharmaceuticals Limited35.60bn6.75bn401.43bn3.21k59.8424.0053.9911.2739.6039.60209.3198.741.012.5914.8511,088,370.0019.2411.0136.0917.8861.7055.7718.9612.251.38554.800.0088192.076.212.00-2.915.78-36.029.86
Glenmark Pharmaceuticals Ltd122.48bn-10.18bn413.80bn14.99k--4.90--3.38-36.13-31.05434.11299.290.69511.534.048,171,082.00-5.641.02-8.511.4365.6459.47-8.111.431.002.560.174156.981.983.67-1,018.93---5.894.56
Data as of Nov 22 2024. Currency figures normalised to Piramal Pharma Ltd's reporting currency: Indian Rupee INR

Institutional shareholders

20.70%Per cent of shares held by top holders
HolderShares% Held
HDFC Asset Management Co. Ltd. (Invt Mgmt)as of 29 Jul 202493.53m7.06%
East Bridge Capital Management L.P.as of 06 Sep 202447.77m3.60%
The Caisse de d�p�t et placement du Qu�becas of 29 May 202343.31m3.27%
Life Insurance Corporation of India (Investment Portfolio)as of 30 Jun 202424.44m1.84%
The Vanguard Group, Inc.as of 06 Nov 202420.74m1.56%
Canara Robeco Asset Management Co. Ltd.as of 31 Oct 202412.38m0.93%
Dimensional Fund Advisors LPas of 07 Nov 20249.53m0.72%
BlackRock Fund Advisorsas of 07 Nov 20248.49m0.64%
Franklin Templeton Asset Management (India) Pvt Ltd.as of 31 Oct 20247.80m0.59%
HSBC Asset Management (India) Pvt Ltd.as of 31 Oct 20246.48m0.49%
More ▼
Data from 30 Sep 2024 - 31 Oct 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.